The graft-versus-host disease (GVHD) treatment market value will increase from $297 million in 2013 to $407 million by 2018, at a Compound Annual Growth Rate (CAGR) of 6.59%, according to research and consulting firm GlobalData. The company’s latest report* states …
This new report provides strategic directions of global flavor and fragrance companies. The report presents:
- Business goals and strategies, including internal expansion, acquisitions, and divestitures.
- Specific business, new product development and marketing objectives and strategies.
- Major strengths and weaknesses.
- Anticipated acquisitions, joint ventures and divestitures.
The companies analyzed in the report: Firmenich, Givaudan, T. Hasegawa, IFF, Mane, Quest, Robertet, Sensient, Symrise, and Takasago